ExCellThera announces publication in The Lancet Haematology highlighting excellent clinical results of ECT-001 in patients with haematological malignancies
06 nov. 2019 07h00 HE
|
ExCellThera
MONTREAL, Nov. 06, 2019 (GLOBE NEWSWIRE) -- ExCellThera Inc., an advanced biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use,...
ExCellThera enters into a manufacturing and collaboration agreement with New York Blood Center
07 mai 2019 08h05 HE
|
ExCellThera
MONTREAL, May 07, 2019 (GLOBE NEWSWIRE) -- ExCellThera Inc., an advanced clinical stage biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for...
ExCellThera’s lead technology, ECT-001, receives FDA Regenerative Medicine Advanced Therapy (RMAT) designation
23 avr. 2019 08h05 HE
|
ExCellThera
MONTREAL, April 23, 2019 (GLOBE NEWSWIRE) -- ExCellThera Inc., an advanced clinical stage biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for...
ExCellThera announces clearance by FDA and Health Canada for ECT-001 in new clinical trials in United States and Canada for the treatment of leukemia
25 mars 2019 08h07 HE
|
ExCellThera
MONTREAL, March 25, 2019 (GLOBE NEWSWIRE) -- ExCellThera Inc., a clinical stage biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for...
ExCellThera receives FDA orphan drug designation for ECT-001 for the prevention of graft-versus-host disease
17 déc. 2018 08h05 HE
|
ExCellThera
MONTREAL, Dec. 17, 2018 (GLOBE NEWSWIRE) -- ExCellThera Inc., a biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, announced...
ExCellThera announces results of clinical trial using ECT-001 for blood cancers
04 déc. 2018 07h05 HE
|
ExCellThera
MONTREAL, Dec. 04, 2018 (GLOBE NEWSWIRE) -- ExCellThera Inc., a biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, today...
ExCellThera announces clinical trial results using ECT-001 to be presented at ASH 2018 annual meeting
08 nov. 2018 07h05 HE
|
ExCellThera
MONTREAL, Nov. 08, 2018 (GLOBE NEWSWIRE) -- ExCellThera Inc., a biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, today...
Final patient receives treatment in stem cell clinical trial for severe blood cancers
27 juin 2018 08h50 HE
|
ExCellThera
MONTREAL, June 27, 2018 (GLOBE NEWSWIRE) -- ExCellThera Inc., a biotechnology company delivering molecules and bioengineering solutions to expand blood stem cells for therapeutic use, announced...